Cutaneous T-Cell Lymphoma (CTCL) Active Not Recruiting Phase 1 Trials for Capecitabine (DB01101)

Also known as: Cutaneous T Cell Lymphoma (CTCL) / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma / Cutaneous T Cell Lymphoma / Cutaneous T-Cell Lymphomas / CTCL / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03775525Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast CancerTreatment